Barclays Maintains Overweight on RXO, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 71.6%

Neg 0% Neu 0% Pos 71.6%

Barclays analyst Brandon Oglenski maintains RXO (NYSE:RXO) with a Overweight and raises the price target from $17 to $20.